Nabriva Therapeutics Management

Management criteria checks 2/4

Nabriva Therapeutics' CEO is J. Naftzger, appointed in Sep 2021, has a tenure of 1.58 years. directly owns 0.009% of the company’s shares, worth €406.77. The average tenure of the management team and the board of directors is 2.2 years and 5.8 years respectively.

Key information

J. Naftzger

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.6yrs
CEO ownership	0.009%
Management average tenure	2.2yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO

J. Naftzger (55 yo)

1.6yrs

Tenure

Mr. J. Christopher Naftzger, Esquire, BA, JD, serves as General Counsel and Secretary of Nabriva Therapeutics plc since September 01, 2021 and serves as its Interim Chief Executive Officer since January 15...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Colin Broom	Director	5.6yrs	US$40.00k	0.043% $ 2.0k
J. Naftzger	Interim CEO	1.6yrs	no data	0.0088% $ 406.8
Daniel Dolan	Chief Financial Officer	2.1yrs	US$555.69k	0% $ 0
Jodi VanDerveer	Senior VP & Head of Human Resources	2.3yrs	no data	no data

2.2yrs

Average Tenure

55yo

Average Age

Experienced Management: NTY's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Colin Broom	Director	5.8yrs	US$40.00k	0.043% $ 2.0k
Daniel Burgess	Independent Chairman of the Board	5.8yrs	US$90.00k	0.013% $ 602.5
Mark H. Corrigan	Independent Director	1.8yrs	US$50.00k	0.0090% $ 418.4
Stephen Webster	Independent Director	5.8yrs	US$65.00k	0.014% $ 662.0
Steven Gelone	Director	2.1yrs	US$579.23k	0.041% $ 1.9k
Charles Rowland	Independent Director	5.8yrs	US$55.00k	0.019% $ 885.6
Theodore Schroeder	Director	4.7yrs	US$753.56k	0.26% $ 12.3k
Lisa Dalton	Independent Director	1.8yrs	US$47.50k	0.011% $ 528.6
Carrie Bourdow	Independent Director	5.8yrs	US$52.50k	0.012% $ 575.1

5.8yrs

Average Tenure

61yo

Average Age

Experienced Board: NTY's board of directors are considered experienced (5.8 years average tenure).

Nabriva Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

Less than half of directors are independent

Less than half of directors are independent

CEO & Director recently bought €51k worth of stock

Recent updates

Nabriva Therapeutics plc Files Form 15

Nasdaq to Delist the Ordinary Shares of Nabriva Therapeutics

Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index

Nabriva Therapeutics Receives A Delisting Determination Letter from Nasdaq

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc announced delayed 10-Q filing

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc Announces Positive Topline Results from Phase 1 Trial of XENLETA (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Nabriva Therapeutics plc Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q2, 2022 Results on Aug 03, 2022

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

The Nasdaq Stock Market LLC Approves Nabriva Therapeutics' Transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2021)

Nabriva Therapeutics plc to Report Q1, 2022 Results on May 05, 2022

No longer forecast to breakeven

Nabriva Therapeutics plc Announces First Patient Enrolled in Phase 1 Trial of Xenleta® (Lefamulin) in Adult Patients with Cystic Fibrosis

Full year 2021 earnings released: US$1.14 loss per share (vs US$5.41 loss in FY 2020)

No longer forecast to breakeven

Less than half of directors are independent

Forecast to breakeven in 2024

Less than half of directors are independent

Forecast to breakeven in 2024

CEO & Director recently bought €51k worth of stock

Less than half of directors are independent

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)

Less than half of directors are independent

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020)

Independent Director George Talbot has left the company

Less than half of directors are independent

No longer forecast to breakeven

Sinovant Sciences and Nabriva Therapeutics plc Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020)

Nabriva Therapeutics plc has completed a Follow-on Equity Offering in the amount of $33.7 million.

Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)

Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019)

Nabriva Therapeutics Appoints Steven Gelone to Its Board of Directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age